ТОП просматриваемых книг сайта:
Anti-Aging Therapeutics Volume XV. A4M American Academy
Читать онлайн.Название Anti-Aging Therapeutics Volume XV
Год выпуска 0
isbn 9781934715154
Автор произведения A4M American Academy
Жанр Медицина
Издательство Ingram
Shalet SM, Brennan BM, Reddingius RE. Growth hormone therapy and malignancy. Horm Res 1997; 48 Suppl 4:29-32
Slonim AE et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000 Jun 1; 342(22):1633-
Soares DV, Spina LD, de Lima Oliveira Brasil RR, Lobo PM, Salles E, Coeli CM, Conceição FL, Vaisman M. Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome. Pituitary. 2006;9(2):127-35.
Stochholm, K et al. Mortality and GH Deficiency a Nationwide Study. European Journal of Endocrinology. (2007)157 9-18
Strassberger C et al. How robust are laboratory measures of growth hormone status? Hormone Research 2005; 64:1-
Sugimoto T et al. Effect of recombinant human growth hormone in elderly osteoporotic women. Clin Endocrinol (Oxf) 1999 Dec; 51(6):715-724
Svensson J et al. Body composition and quality of life as markers of the efficacy of growth hormone replacement therapy in adults.Horm Res 2001;55 Suppl 2:55-60
Svensson J, Mattsson A, Rosén T, Wirén L, Johannsson G, Bengtsson BA, Koltowska Häggström M; Swedish KIMS National Board. Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Growth Horm IGF Res. 2004;14:207-215.
Swerdlow A. et al. Growth Hormone Treatment of Children with Brain Tumors and Risk of Tumor Recurrence. The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 12, December 2000
Takala J et al. Increased mortality associated with GH treatment in critically ill adults. NEJM 1999; 341:785-
Thum T et al. Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-1. J Clin Endocrinol Metab. 2007 Aug 28
Tivesten, A The Growth Hormone Secretagogue Hexarelin Improves Cardiac Function in Rats after Experimental Myocardial Infarction. Endocrinology, January 2000, p. 60-66 Vol. 141, No. 1
Toogood A. et al. Growth Hormone Replacement Therapy in the Elderly with Hypothalamic-Pituitary Disease: A Dose-Finding Study. J Clin Endocrinol Metab 84: 131–136, 1999
Torella D et al. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ Res. 2004 Mar 5;94(4):514-24
Zoltan Ungvari and Anna Csiszar. “The Emerging Role of IGF-1 Deficiency in Cardiovascular Aging: Recent Advances.” J Gerontol A Biol Sci Med Sci (2012) 67A (6): 599-610.
Valimaki MJ et alEffects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur J Endocrinol 1999 Jun; 140(6):545-54
van Dam PS Somatropin therapy and cognitive function in adults with growth hormone deficiency: a critical review. Treat Endocrinol. 2006; 5(3):159-70
Van Der Lely et al. Use of human GH in elderly patients with accidental hip fracture. Eur J Endocrinol 2000 Nov; 143(5):585-592
Wang P et al. The role of endotoxin, TNF-alpha, and IL-6 in inducing the state of growth hormone insensitivity. World J Gastroenterol 2002 Jun; 8(3):531-6 AIM:
Wren AM et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion, Endocrinology 2000 Nov;141(11):4325-8
Yancy CW, Jessup M, Bozkurt B, Masoudi FA, et al; ACCF/AHA Task Force Members. “2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.” J Am Coll Cardiol. 2013 Jun 5.
DHEA
Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, Ouchi Y. Association of plasma dehydroepiandrosterone-sulfate levels with endothelial function in postmenopausal women with coronary risk factors. Hypertens Res. 2008; 31:69-74.
Baulieu E.E., Thomas G., Legrain S., Lahlou N., Roger M., Debuire B., Faucounau V., Girard L., Hervy M.P., Latour F., Leaud M.C., Mokrane A., Pitti-Ferrandi H., Trivalle C., de Lacharriere O., Nouveau S., Rakoto-Arison B., Souberbielle J.C., Raison J., Le Bouc Y., Raynaud A., Girerd X., Forette F. (2000). Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA, 97(8):4279–4284.
Baulieu E.E. (1996). Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metabo, 81:3147–3151.
Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986;315:1519-1524.
Barrett-Connor E, Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation. 1995;91:1757-1760.
Chiu KM, Schmidt MJ, Havighurst TC, Shug AL, Daynes RA, Keller ET, Gravenstein S. Correlation of serum L-carnitine and dehydro-epiandrosterone sulphate levels with age and sex in healthy adults. Age Ageing. 1999;28:211-216.
Ciolino H, MacDonald C, Memon O, Dankwah M, Yeh GC. Dehydroepiandrosterone inhibits the expression of carcinogen-activating enzymes in vivo. Int J Cancer. 2003;105:321-325.
Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, Kelloff G, Lubet R. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res. 2001;61:7449-7455.
de Heredia FP, Cerezo D, Zamora S, Garaulet M. Effect of dehydroepiandrosterone on protein and fat digestibility, body protein and muscular composition in high-fat-diet-fed old rats. Br J Nutr. 2007;97:464-470.
Ho HY, Cheng ML, Chiu HY, Weng SF, Chiu DT. Dehydroepiandrosterone induces growth arrest of hepatoma cells via alteration of mitochondrial gene expression and function. Int J Oncol. 2008;33:969-977.
Hursting SD, Perkins SN, Haines DC, Ward JM, Phang JM. Chemoprevention of spontaneous tumorigenesis in p53-knockout mice. Cancer Res. 1995;55:3949-3953.
Kumar P, Taha A, Sharma D, Kale RK, Baquer NZ. Effect of dehydroepiandrosterone (DHEA) on monoamine oxidase activity, lipid peroxidation and lipofuscin accumulation in aging rat brain regions. Biogerontology. 2008;9:235-246. Erratum in: Biogerontology. 2008;9:283-284.
Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994;78:1360-1367. Erratum in: J Clin Endocrinol Metab 1995;80:2799.
Page JH, Ma J, Rexrode KM, Rifai N, Manson JE, Hankinson SE. Plasma dehydroepiandrosterone and risk of myocardial infarction in women. Clin Chem. 2008;54:1190-1196.
Rabijewski M, Zgliczyński W. Positive effects of DHEA therapy on insulin resistance and lipids in men with angiographically verified coronary heart disease--preliminary study]. Endokrynol Pol. 2005 Nov-Dec;56(6):904-10.
Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE, Kelloff GJ, McCormick DL. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res. 1999;59:3084-3089.
Reiter WJ, Pycha A, Schatzl G, Pokorny A, Gruber DM, Huber JC, Marberger M. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology. 1999;53:590-594; discussion 594-5.
Stuckelberger A. (2008). Anti-Ageing Medicine : Myths and Chances. ETH Verlag, Zurich, Switzerland.
Yang S, Fu Z, Wang F, Cao Y, Han R. Anti-mutagenicity activity of dehydroepiandrosterone. Zhonghua Zhong Liu Za Zhi. 2002;24:137-140. Chinese.
Testosterone
Agarwal PK et al. Testosterone replacement therapy after